SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 1.370-2.8%Jan 23 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BulbaMan who wrote (74)8/15/1997 4:30:00 PM
From: nelli   of 3578
 
More briefing.com comments:

GERON CORP (GERN) 16 +9 1/2. Issue has more than doubled on news that researchers have identified a
protein key to the uncontrolled growth of cancer cells, which could eventually lead to new forms of
cancer-fighting drugs.. Telomerase has previously been shown to be active in all types of cancer. Because
telomerase is required for cancer cells to proliferate, Geron is seeking to discover anti-cancer drugs designed to
inhibit telomerase. The discovery will allow drug companies to more rapidly test compounds that
may inhibit telomerase. Since the protein is also associated with the aging of sales, researchers envision
additional applications of the technology. The stock posted impressive early gains in the 30%-40% range in early
trading. However, the buying interest accelerated after CNBC's Joe Kernan made mention of the stock. Now the
stock has traded 3.50 million shares, obliterating yesterday's volume total of 135,200 shares. As of the time of
this story, interest in the stock does not appear to have peaked, but is certainly slowing. One should expect
short sellers to ready themselves to borrow stock and unload once they feel the issue has run out of steam.
For a recent example of how this situation may play out over the next several weeks, see the attached chart of
Aviron (AVIR 25 13/16 -1/16). Recent examples suggest that it makes more since as a short-seller to wait for the
trend to reverse, rather than attempting to be a hero by calling a top.
****

I suggest comparing ONXX around October 96 than AVIR. But if GERN has a secondary offering coming up (which they might cause cash seems to be short) then I'm out the door! AVIR has a product completing Phase III but GERN has no product to mention of. I think it gaps up a little Monday morning and then the bubble pops.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News